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Background: In an effort to establish the lowest effective dose of desvenlafaxine (administered as desvenlafaxine
succinate), we assessed the efficacy, safety, and tolerability of 10- and 50-mg/day desvenlafaxine vs placebo for the
treatment of major depressive disorder.
Methods: Adult outpatients with DSM-IV–defined major depressive disorder and a 17-item Hamilton Rating Scale
for Depression (HAM-D17) total score ≥20 were randomly assigned to receive placebo or desvenlafaxine (10 or 50
mg/day) after a 6- to 14-day single-blind placebo lead-in period in an 8-week, phase 3, fixed-dose trial. The primary
efficacy measure was change from baseline in the HAM-D17 score analyzed using analysis of covariance. Efficacy
analyses were conducted with the intent-to-treat population, using the last observation carried forward.
Results: The intent-to-treat population included 673 patients. Change from baseline to final evaluation in adjusted
HAM-D17 total scores was not significantly different comparing desvenlafaxine 10 mg/day (-9.28) and desvenlafaxine
50 mg/day (-8.92) with placebo (-8.42). There were no differences among treatment groups in the rates of
treatment response or remission. Discontinuations due to adverse events occurred in 1.8%, 0.9%, and 1.8% of
patients in the placebo and desvenlafaxine 10- and 50-mg/day groups, respectively. Overall rates of treatment-
emergent adverse events with both doses were similar to placebo.
Conclusions: Both doses of desvenlafaxine failed to separate from placebo. However, in a companion study
reported separately, desvenlafaxine 50 mg, but not 25 mg, separated from placebo. Taken together, these studies
suggest that 50 mg is the minimum effective dose of desvenlafaxine for the treatment of major depressive
disorder.
ClinicalTrials.gov Identifier: NCT00863798 http://clinicaltrials.gov/ct2/show/NCT00863798?term=00863798&rank=1.
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Major depressive disorder (MDD) is a chronic, recur-
rent, and potentially disabling illness [1]. In the United
States, the estimated lifetime prevalence of MDD is 17%
[2] and the lifetime risk of developing MDD is estimated
to be 10% to 25% in women and 5% to 12% in men [3].
There is a continuing need for antidepressant agents* Correspondence: MRLiebowitz@yahoo.com
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reproduction in any medium, provided the orthat are effective, safe, and well tolerated for both acute
and long-term management of MDD.
Desvenlafaxine (administered as desvenlafaxine succin-
ate) was approved by the United States Food and Drug
Administration in 2008 for the treatment of adult patients
with MDD [4] and is in the serotonin-norepinephrine re-
uptake inhibitor (SNRI) class of antidepressants. The effi-
cacy and safety of desvenlafaxine at doses of 50, 100, 200,
and 400 mg/day for the treatment of MDD has been eval-
uated in short-term, randomized, double-blind, placebo-
controlled trials in adult outpatients with MDD [5-12].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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venlafaxine 50 mg/day (recommended dose) for the treat-
ment of MDD in adult outpatients at 25 centers in the
United States and 44 centers in Europe and South Africa
[8,9]. Across all clinical studies of desvenlafaxine, doses
above 50 mg/day were effective, but conferred no additional
benefit; higher doses were associated with increased rates
of adverse events (AEs). Treatment with desvenlafaxine was
generally well tolerated in these studies.
The purpose of the current study was to evaluate the
clinical effectiveness of lower dose desvenlafaxine (10
mg/day) and the recommended dose (50 mg/day) com-
pared with placebo in outpatients with MDD. The study
was designed to compare each desvenlafaxine dose group
with placebo separately, with no comparisons between the
desvenlafaxine 10- and 50-mg/day doses. The 17-item
Hamilton Rating Scale for Depression (HAM-D17) total
scores over 8 weeks, change from baseline in observer-
rated depression scales and self-reported quality of life out-
comes, and the safety/tolerability of desvenlafaxine were
assessed. A companion study of low dose desvenlafaxine
(25 and 50 mg/day) vs placebo was also recently performed
and will be published [13].
Methods
Study design
This was a phase 3, double-blind, randomized, placebo-
controlled, parallel-group study conducted in adult out-
patients with MDD at 25 sites including private and
institutional practice and research centers, within the
United States between April 2009 and March 2010
(registered with ClinicalTrials.gov prior to first-subject
first-visit, study identifier NCT00863798). The protocol
received institutional review board or independent eth-
ics committee approval before the study began, and the
study was conducted according to the principles in the
Declaration of Helsinki. All participants provided written,
informed consent prior to study enrollment. The study in-
cluded a 6- to 14-day single-blind placebo lead-in period
and 8 weeks of double-blind treatment with desvenlafaxine
10 mg/day, desvenlafaxine 50 mg/day, or placebo. Patients
returned for follow-up visits approximately 7 and 14 days
after the last dose of study medication (for safety assess-
ments only); there was no taper phase.
Study population
Inclusion criteria
Eligible participants were medically healthy adult outpa-
tients aged 18 years or older with a primary diagnosis of
MDD based on criteria from the Diagnostic and Statis-
tical Manual of Mental Disorders, 4th edition (text revi-
sion) confirmed through an investigator’s psychiatric
clinical interview. Patients must also have had depressive
symptoms ≥30 days before screening, total score ≥20 onthe HAM-D17 at screening and baseline visit, score ≥2
on item 1 (depressed mood) of HAM-D17 at screening
and baseline, and score ≥4 on the Clinical Global Impres-
sions–Severity scale (CGI-S) at screening and baseline.
Exclusion criteria
Patients were excluded if they had received treatment
with desvenlafaxine at any time in the past; known
hypersensitivity to venlafaxine; significant risk of suicide;
score of >3 on HAM-D17 item 3 (suicide) at screening
or baseline; significant placebo response (≥25% decrease
from screening in HAM-D17 total score at baseline); his-
tory of seizure disorder, gastrointestinal disease, or neo-
plastic disorder; or major acute illness within 90 days prior
to screening. Patients with current psychoactive substance
abuse or dependence (including alcohol), manic episode,
posttraumatic stress disorder, obsessive-compulsive dis-
order, or a lifetime diagnosis of bipolar or psychotic dis-
order; current generalized anxiety disorder, panic disorder,
or social anxiety disorder considered by the investigator to
be primary (causing a higher degree of distress or impair-
ment than MDD); or a clinically important personality dis-
order were also excluded, as were patients with any
unstable hepatic, renal, pulmonary, cardiovascular (includ-
ing uncontrolled hypertension or myocardial infarction
within 180 days of the screening visit), ophthalmologic,
neurologic, or other medical condition. Prohibited con-
comitant treatments included electroconvulsive therapy or
formal psychotherapy (exclusive of supportive therapy)
within 180 days of study day 1; venlafaxine within 90 days;
investigational drugs or procedures, antipsychotics, or flu-
oxetine with 30 days; other antidepressants, monoamine
oxidase inhibitors, anxiolytics, sumatriptan, naratriptan,
zolmitriptan, and drugs with a similar mechanism of ac-
tion, or tryptophan supplements within 14 days; and seda-
tive hypnotics (other than zolpidem or zaleplon, allowed
only during the first 14 days after randomization), herbal
products intended to treat anxiety, insomnia, and de-
pression, other psychotropic drugs or substances, or
initiation of treatment with nonpsychopharmacologic
drugs with psychotropic effects within 7 days of study
day 1. Nonpsychopharmacologic drugs with psycho-
tropic effects were permitted if the patient has been re-
ceiving a stable dose of the drug for at least 90 days
before study day 1 and is expected to continue taking
the drug without dose changes throughout the study.
Treatment protocol
During the placebo lead-in period, patients received single-
blind placebo for up to 14 days corresponding to the time
in screening of 10±4 days. Following the placebo lead-in
period, patients were randomly assigned to receive 8 weeks
of double-blind treatment with placebo, desvenlafaxine 10
mg/day, or desvenlafaxine 50 mg/day with no titration
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generated by the Clinical Biostatistics Section of Pfizer Inc,
(formerly Wyeth Research). Study site personnel called an
automated system to receive subject randomization num-
ber and package number.Efficacy and safety assessments
The primary efficacy end point was change from base-
line in HAM-D17 total score (observer-rated) at the final
on-therapy (FOT) evaluation. HAM-D17 total scores
were assessed at screening, baseline, and study days 7,
14, 21, 28, 42, and 56 (or upon early withdrawal from
the study). The key secondary efficacy end point was the
score at FOT on the Clinical Global Impressions–
Improvement (CGI-I) [14]. Other efficacy variables
included change from baseline in CGI-S, Montgomery-
#506;sberg Depression Rating Scale (MADRS) total
score [15], and 6-item Hamilton Rating Scale for Depres-
sion (HAM-D6) score, as well as HAM-D17, MADRS, and
CGI-I response rates and HAM-D17 remission rates.
Scores were determined at the following time points:
MADRS at baseline, and study days 14, 28, and 56 (or
early withdrawal); CGI-S at screening, baseline, and study
days 7, 14, 21, 28, 42, and 56 (or early withdrawal); CGI-I
scores at study days 7, 14, 21, 28, 42, and 56 (or early with-
drawal). Response on the HAM-D17, and MADRS were
defined as ≥50% decrease in the respective total score
from baseline; CGI-I response was defined as a score ≤2;
HAM-D17 remission was defined as total score ≤7.
Patient-rated secondary efficacy outcome measures in-
cluded mean change from baseline in total scores on the
World Health Organization 5-item Well-Being Index
(WHO-5) and Sheehan Disability Scale (SDS; functional
outcomes measures including work, social life, family life)
SDS and WHO-5 assessments were obtained at baseline
and study days 14, 28, and 56 (or early withdrawal). No ef-
ficacy assessments were collected at the follow-up visit.
Safety assessments included monitoring of treatment-
emergent adverse events (TEAEs), discontinuations due to
AEs, and serious AEs (SAEs). AEs were evaluated at
screening, baseline, study days 7, 14, 21, 28, 42, and 56,
and at the 2 follow-up visits (study days 63 and 70).Statistical analysis
The biostatistics section of Pfizer (formerly Wyeth) car-
ried out statistical analysis. It was estimated that a sam-
ple size of 216 per group would be needed with 2-sided
ά=0.05 to provide 90% power to detect a difference be-
tween desvenlafaxine and placebo of 2.5 units of change
(standard deviation of 8.0 units) on the HAM-D17 from
baseline to FOT. To attain this sample size, the enroll-
ment target was approximately 226 people randomized
to each group.The primary efficacy end point (change from baseline
in HAM-D17 total score at the FOT evaluation for
desvenlafaxine 10 mg/day or 50 mg/day vs placebo) was
analyzed using analysis of covariance (ANCOVA) model
with treatment as factor and baseline HAM-D17 total
score as covariate for the intent-to-treat (ITT) population.
Comparisons were made between each desvenlafaxine dose
and placebo; the study was neither designed nor powered
to compare the desvenlafaxine 10- and 50-mg/day dose
arms. The ITT population included all randomly assigned
patients who had a baseline primary efficacy evaluation,
had taken at least 1 dose of double-blind study medication,
and had at least 1 primary evaluation after the first dose of
double-blind study medication. The key secondary end
point (CGI-I score at the final on-therapy evaluation), was
analyzed as a categorical variable using the Cochran-
Mantel-Haenszel row-mean-score-difference test using
ridit scores. Continuous secondary efficacy end points
(CGI-S, MADRS total scores, HAM-D6 total scores, SDS
total scores and subcomponents, and WHO-5 total scores)
at the FOT evaluation were analyzed using ANCOVA with
treatment as factor and corresponding baseline value as co-
variate. Response and remission rates for HAM-D17 and
MADRS were analyzed with a logistic regression model
with treatment as factor and baseline score as covariate.
CGI-I response rate was analyzed using logistic regression
with treatment as factor. All analyses were based on the
ITT population with last observation carried forward
(LOCF)-imputed data for missing assessments. Statistical
testing was done 2-sided at the α=0.05 level. For the pri-
mary efficacy end point, the Hochberg step-up procedure
was used to control for multiplicity associated with mul-
tiple active treatments. Testing of the key secondary end
point occurred only when both active doses were superior
to placebo on the primary end point to control the study-
wise type I error rate across the primary and the key sec-
ondary end point of CGI-I, as well as across the 2 active
dose arms. In this case, multiplicity arising from testing the
key secondary end point in both doses would be controlled
by a Hochberg step-up procedure. For other secondary
efficacy end points, pairwise p-values will be reported with-
out multiplicity control. For the safety population, sum-
mary tables and listings were generated for AEs, TEAEs,
and SAEs. The safety population included all randomly




A total of 898 patients were screened, 76 did not meet
entry criteria and 18 were enrolled but did not take pla-
cebo lead-in (Figure 1). Of 804 patients who took the
placebo lead-in, 122 withdrew prior to randomization,
while 682 were randomized to treatment: 227 to
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desvenlafaxine 50 mg/day. Of the 682 randomized pa-
tients, 9 did not receive treatment, leaving a sample of
673 patients who received at least 1 dose of study medica-
tion (safety population). The ITT population, consisting of
patients who received at least one dose of study medica-
tion and had one post-baseline assessment, also included
673 subjects. Demographic and baseline clinical character-
istics were similar among the desvenlafaxine 10 mg/day,
desvenlafaxine 50 mg/day, and placebo treatment groups
(Table 1). Seventy-eight (11.6%) patients discontinued
from treatment prior to the end of the study (placebo
group, n=28/223 [12.6%]; desvenlafaxine 10 mg/day,
n=28/226 [12.4%]; desvenlafaxine 50 mg/day, n=22/224
[9.8%]). The most common reasons for early discontinu-
ation were withdrawal by patient, lost to follow-up, and
lack of efficacy.
Efficacy evaluation
Figure 2 shows the adjusted mean scores on the HAM-





Desvenlafaxine 10 mg/d (n
Did not receive (n=2)
Placebo (n=227) 
Did not receive (n=4)
Discontinuations (n=28
Adverse event (n=2) 
Failed to return (n=1) 
Lost to follow-up (n=9) 
Protocol violation (n=1) 
Investigator request (n=2)  
Lack of efficacy (n=3) 
Patient withdrawal (n=7) 
Other (n=3) 
Discontinuations (n=28) 
Adverse event (n=5) 
Failed to return (n=2) 
Lost to follow-up (n=6) 
Protocol violation (n=0) 
Investigator request (n=1) 
Lack of efficacy (n=4) 
Patient withdrawal (n=8) 
Other (n=2) 
Safety Population (n=2Safety Population (n=223)
a
Patients may have failed to meet more than 1 eligibility requirement.
804)
Figure 1 Population study flow.primary efficacy end point of the adjusted mean change
from baseline in the HAM-D17 total score at the FOT
evaluation did not reach statistical significance for patients
in the desvenlafaxine 10 mg/day (-9.28) or desvenlafaxine
50 mg/day (-8.92) treatment groups vs placebo (-8.42;
P=0.175 and P=0.421, respectively). The adjusted mean dif-
ference (95% confidence interval [CI]) vs placebo was 0.86
(-0.38, 2.10) and 0.51 (-0.73, 1.75) for the desvenlafaxine 10
mg/day and 50 mg/day treatment groups, respectively.
For the key secondary efficacy end point of CGI-I
score at FOT, percentages of patients who were rated as
“very much improved” or “much improved” were 55.3%
and 48.2% in the desvenlafaxine 10 mg/day and 50 mg/
day treatment groups, respectively, compared with 46.2%
in the placebo group; no significant differences were
observed among the desvenlafaxine treatment groups vs
placebo before and after the multiplicity control (Figure 3).
Similarly, the change from baseline in CGI-S, MADRS
total score, and HAM-D6 total score did not differ be-
tween the desvenlafaxine 10 mg/day and 50 mg/day
treatment groups vs placebo (Table 2). In addition, P-=898) 





Previous desvenlafaxine use (n=2) 
Significant risk of suicide (n=3) 
Comorbidities (n=33) 
Clinically important abnormalities (n=8) 
Concomitant meds (n=3) 
Failure to return/removal of consent (20) 
Failure to meet DSM-IV-TR criteria (n=16) 
Did not have depressive symptoms for ≥30 days (n=2) 
HAM-D
17 
score out of range at screening or baseline (n=36) 
CGI-S score <4 at screening or baseline (n=16) 
n 
=228) Desvenlafaxine 50 mg/d (n=227) 
Did not receive (n=3)
) Discontinuations (n=22) 
Adverse event (n=4) 
Failed to return (n=0) 
Lost to follow-up (n=5) 
Protocol violation (n=1) 
Investigator request (n=1)  
Lack of efficacy (n=6) 
Patient withdrawal (n=4) 
Other (n=1)
26) Safety Population (n=224)
Did not take placebo lead-in  
(n=18)
Table 1 Demographic and baseline characteristics of safety population by treatment group
Characteristic Placebo Desvenlafaxine Desvenlafaxine
(n = 223) 10 mg/d (n = 226) 50 mg/d (n = 224)
Age, y 42 ± 13 41 ± 14 43 ± 14
Age group, n (%)
18-64 y 215 (96) 212 (94) 213 (95)
>64 y 8 (4) 14 (6) 11 (5)
Female, n (%) 139 (62) 135 (60) 135 (60)
Race, n (%)
White 176 (79) 199 (88) 177 (79)
Black 38 (17) 20 (9) 37 (17)
Asian 4 (2) 3 (1) 2 (1)
Other 5 (2) 4 (2) 8 (4)
Weight, kg 87 ± 24 88 ± 27 91 ± 26
Body mass index, kg/m2 30 ± 7 31 ± 9 32 ± 8
Baseline HAM-D17 score 23 ± 3 23 ± 2 23 ± 3
Duration of current depressive episode, mo 34 ± 81 26 ± 48 31 ± 76
Data are presented as mean ± standard deviation unless otherwise indicated.
d, day; HAM-D17, 17-item Hamilton Rating Scale for Depression; ITT, intent-to-treat; kg, kilogram; m, meter; mo, months; y, years.
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day or 50 mg/day treatment groups were compared with
placebo for rates of HAM-D17 response (44%, 41%, and
38%, respectively); HAM-D17 remission (23% and 17%
vs 19%, respectively); MADRS response (42% and 41% vs
38%, respectively); or CGI-I response (55% and 48% vs
46%, respectively). However, pairwise p-values vs. placebo
were below 0.05 for the adjusted mean change from base-
line in SDS Work Studies component scores for both
desvenlafaxine 10 mg/day and 50 mg/day vs placebo
(change of -1.10, -1.14, and -0.61, respectively; Table 2). p-
values for the adjusted mean change from baseline in























Figure 2 Adjusted mean scores on HAM-D17 (ANCOVA), LOCF data, ITcomponents were also below 0.05 for desvenlafaxine 10
mg/day vs placebo.
Safety evaluation
Treatment-emergent adverse events were reported by
147 patients (66%) in the placebo group, 155 patients
(69%) in the desvenlafaxine 10 mg group, and 154
patients (69%) in the desvenlafaxine 50 mg/day group.
The most common TEAEs (incidence ≥5% in any treat-
ment group) during the on-therapy period are shown in
Table 3. Adverse events resulted in discontinuation of
treatment for 10 of 673 patients (1.5%) overall (4 pa-


































Figure 3 CGI-I at final on-therapy visit (LOCF), ITT population.
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patients [1.8%] in the desvenlafaxine 50 mg/day treat-
ment group) during the on-therapy period. Serious ad-
verse events were reported by 5 patients (0.7%). Of these
5 patients, 4 had an SAE during the on-therapy period
(placebo, n=2 [noncardiac chest pain and appendicitis in
1 patient; scrotal abscess in 1 patient]; desvenlafaxine 10
mg/day, n=1 [urinary retention]; and desvenlafaxine 50
mg/day, n=1 [pulmonary embolism]). The pulmonary
embolism in this 53-year-old female was determined by
the study investigator to be related to study medication.
She had a nonproductive cough that began between
screening and randomization which did not respond to a
10-day course of antibiotics. On study days 8 to 11 she
reported edema in the ankles. A CT scan on day 19
showed pulmonary embolism in the right lung. SheTable 2 Adjusted mean change from baseline in total scores
ITT Population
Secondary outcome Placebo
MADRS total score –9.87 (0.63)
CGI-S total score –1.08 (0.07)
HAM-D6 total score –4.75 (0.27)
SDS total score –2.63 (0.48)
SDS Work Studies component –0.61 (0.17)
SDS Social Life component –1.08 (0.18)
SDS Life/Home Responsibilities –0.98 (0.17)
WHO-5 total score 2.96 (0.36)
†p<0.05 and ‡p<0.01; ANCOVA model using treatment as factor and baseline as cov
CGI-S, Clinical Global Impressions–Severity; HAM-D6, 6-item Hamilton Rating Scale f
MADRS, Montgomery-Åsberg Rating Scale for Depression; SDS, Sheehan Disability Sreceived treatment for the pulmonary embolism and
discontinued from the study on day 20.
Mean changes in vital signs from baseline to the FOT
assessment were not significantly different comparing
desvenlafaxine 10 mg/day or 50 mg/day vs placebo for
supine pulse rate, supine systolic pressure, and supine
diastolic pressure. Mean decreases in weight in the
desvenlafaxine 50 mg/day group were significant com-
pared with baseline and with mean changes in the pla-
cebo group at weeks 1, 2, 3, 4, 6, 8, and FOT, whereas
the desvenlafaxine 10 mg/day group was not signifi-
cantly different from baseline or placebo at any time
point. At FOT, adjusted mean (SE) changes in weight
from baseline were 0.11 (0.16) kg, -0.03 (0.16) kg, and -0
.55 (0.16) kg for the placebo, 10 mg/day, and 50 mg/day
groups, respectively. No participant on placebo, 2 in theon various secondary efficacy outcome measures (LOCF),
Adjusted mean (SE) change from baseline
Desvenlafaxine 10 mg/d Desvenlafaxine 50 mg/d
–11.28 (0.63) –10.76 (0.63)
–1.23 (0.07) –1.11 (0.07)
–5.49 (0.27) –5.19 (0.27)
–4.09 (0.48)† –3.78 (0.49)
–1.10 (0.17)† –1.14 (0.17)†
–1.58 (0.17) † –1.36 (0.18)
–1.43 (0.17) –1.20 (0.17)
4.51 (0.35)‡ 3.73 (0.36)
ariate.
or Depression; ITT, intent to treat; LOCF, last observation carried forward;
cale; WHO-5, World Health Organization 5-item Well-being Index.
Table 3 Number (%) of patients reporting TEAES with







Any TEAE 147 (66) 155 (69) 154 (69)
Gastrointestinal disorders
Constipation 5 (2) 4 (2) 15 (7)
Diarrhea 11 (5) 14 (6) 17 (8)
Dry mouth 11 (5) 17 (8) 20 (9)
Nausea 14 (6) 21 (9) 32 (14)
General disorders
Fatigue 4 (2) 7 (3) 13 (6)
Infections
Upper RTI 11 (5) 18 (8) 12 (5)
Metabolism and nutrition disorders
Decreased appetite 8 (4) 9 (4) 20 (9)
Nervous system disorders
Dizziness 12 (5) 9 (4) 16 (7)
Headache 17 (8) 18 (8) 16 (7)
Psychiatric disorders
Insomnia 8 (4) 11 (5) 15 (7)
RTI, respiratory tract infection; TEAE, treatment-emergent adverse event.
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(1.8%) gained ≥7% of their baseline body weight during
treatment, while 2 (<1%), 5 (2.2%) and 3 (1.3%) lost ≥7%
of their baseline body weight, respectively.Discussion
Desvenlafaxine is an SNRI that has demonstrated effi-
cacy at doses of 50 to 400 mg/day. The objective of the
current study was to evaluate the efficacy and tolerability
of a lower dose of desvenlafaxine (10 mg/day) compared
with placebo in adult outpatients with MDD. Treatment
with desvenlafaxine 10 mg/day did not separate from
placebo on the primary efficacy measure, HAM-D17
improvement from baseline, nor on observer-rated sec-
ondary depression measures. However, patient-related
secondary measures showed improvements from base-
line in scores on the SDS and WHO-5 for patients who
received desvenlafaxine 10 mg/day compared with those
who received placebo. Safety findings for desvenlafaxine
10 and 50 mg/day were similar to those previously
reported for desvenlafaxine treatment [8,9] and were
consistent with known safety findings of other anti-
depressant medications.
Although the efficacy of desvenlafaxine 50 mg has
been demonstrated in previous MDD trials [8,9] in thecurrent study, this dose did not reach statistical signifi-
cance compared with placebo for the primary efficacy
measure. However, it should be noted that approxi-
mately 50% of antidepressant trials of effective drugs fail
to meet clinical superiority vs placebo [16]. A high pla-
cebo response (>30% symptom reduction on the HAM-
D score) [16] and baseline HAM-D score <25 [17] also
may reduce the likelihood of reaching statistical differ-
ences between antidepressant treatment and placebo. In
the current study, the placebo lead-in period used to ex-
clude placebo responders did reduce the magnitude of
mean change in HAM-D17 scores from the approxi-
mately 40% to 45% reductions observed for placebo in
previous MDD trials [8,9]. Nonetheless, participants in
the placebo group in this study had a mean HAM-D17
symptom reduction of 36% over 8 weeks, and both the
placebo and desvenlafaxine 50 mg/day groups had base-
line HAM-D17 scores of ~23.
The strengths of this study include the randomized,
placebo-controlled trial design and the broad range of effi-
cacy and safety measures employed. A wide range of effi-
cacy measures were studied utilizing both observer-rated
(HAM-D17, CGI-I, MADRS) and patient-rated (WHO-5,
SDS) assessment measures. In the current study, there
were no statistical improvements seen with either dose of
desvenlafaxine in the observer-rated measures, but some of
the self-rated measures did show statistical differences vs
placebo. Several features of observer- and self-assessment
tools (e.g., HAM-D17 vs SDS) are important to consider
when interpreting results [18-21]. Observer-rated scales
take advantage of a trained clinical researcher’s ability to
assess the severity of a patient’s symptoms in a clinical con-
text, whereas self-rating scales may be affected by factors
such as the inherent reflection of the patient’s individual
experience, willingness for self-disclosure, self-perception,
language skills, and cognitive capabilities [18]. In addition,
self-ratings may be more likely to take into account symp-
toms not classically considered MDD, such as pain and
anxiety [21]. The self-rated scales in the current study fo-
cused on global well-being and disability rather than de-
pressive symptoms, which may have contributed to the
differences that emerged; however, the lack of concordance
between the observer-rated and patient-rated scales in this
study limits the conclusions that can be drawn about the
efficacy of desvenlafaxine 10 mg/day.
A limitation of the current study was the fixed-dose
design, which did not provide the ability to up-titrate
desvenlafaxine in patients who may have needed or
may have tolerated higher doses, and results may not
be fully generalizable to clinical practice. Another limi-
tation is that no comparisons can be made between
the desvenlafaxine 10 and 50 mg/day doses, since this
study was not designed nor powered to compare the
treatment arms.
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http://www.biomedcentral.com/1471-244X/13/94In the absence of the clinical efficacy of desvenlafaxine
50 mg/day, the results of this study with desvenlafaxine
10 mg/day may be considered inconclusive and the
interpretation of the data is difficult. However, a com-
panion study comparing low-dose desvenlafaxine (25
mg/day) and desvenlafaxine (50 mg/day) with placebo
did support the clinical superiority of desvenlafaxine 50
mg/day over placebo, and found no significant improve-
ment with 25 mg/day in either observer- or patient-
rated measures [13]. The data from the companion study
in concert with the findings obtained in the current
study suggest that desvenlafaxine is not effective at doses
lower than 50 mg/day.
Conclusions
In this phase 3, multicenter, randomized, double-blind
study, neither desvenlafaxine 10 mg/day nor desvenlafaxine
50 mg/day separated from placebo on the primary efficacy
end points in patients with MDD. Treatment with des-
venlafaxine 10 mg/day and 50 mg/day was generally safe
and well-tolerated, with TEAEs observed in this study
comparable to those observed in previously reported phase
3 studies of desvenlafaxine treatment for MDD. These re-
sults, in conjunction with those from a similar study [13],
suggest that doses of desvenlafaxine below 50 mg/day are
not effective for treatment of MDD.
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